Pharvaris (PHVS) News Today $18.76 +0.94 (+5.27%) As of 07/3/2025 02:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Buy" from Brokerages2 hours ago | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Up - What's Next?July 3 at 11:48 AM | marketbeat.comPharvaris (NASDAQ:PHVS) Trading Down 4.9% - What's Next?June 27, 2025 | marketbeat.comPharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National SummitJune 27, 2025 | globenewswire.comPharvaris N.V. (9EN.F) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and Pharvaris (PHVS)June 24, 2025 | theglobeandmail.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...June 16, 2025 | gurufocus.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...June 16, 2025 | gurufocus.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI CongressJune 16, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Given Average Rating of "Buy" by BrokeragesJune 11, 2025 | marketbeat.comCantor Fitzgerald Predicts Pharvaris FY2026 EarningsJune 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Now Covered by Analysts at GuggenheimJune 11, 2025 | marketbeat.comBank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS)June 11, 2025 | marketbeat.comPharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 TrialsJune 10, 2025 | tipranks.comPharvaris Announces Annual Meeting of ShareholdersJune 10, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,838 Shares of Pharvaris (NASDAQ:PHVS)June 10, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for Pharvaris Q2 Earnings?June 9, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Pharvaris (NASDAQ:PHVS)June 5, 2025 | marketbeat.comPharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 TrialsJune 5, 2025 | tipranks.comPharvaris reports promising results for deucrictibant in HAEJune 3, 2025 | investing.comPharvaris reports promising results for deucrictibant in HAEJune 3, 2025 | investing.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?June 3, 2025 | marketbeat.comPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...June 2, 2025 | gurufocus.comPharvaris (PHVS) Spotlights Promising Deucrictibant Data at Key Workshop | PHVS Stock NewsJune 2, 2025 | gurufocus.comPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...June 2, 2025 | gurufocus.comPharvaris Reports Promising Durability Data for Deucrictibant in Treating Hereditary Angioedema and Highlights Potential for Expanded Use in Bradykinin-Mediated AngioedemaJune 2, 2025 | quiverquant.comQPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated AngioedemaJune 2, 2025 | globenewswire.comPharvaris N.V.: Pharvaris Reports First Quarter 2025 Financial Results and Provides Business UpdateJune 1, 2025 | finanznachrichten.dePharvaris (NASDAQ:PHVS) Shares Up 6.7% - Time to Buy?May 30, 2025 | marketbeat.comWoodline Partners LP Makes New Investment in Pharvaris (NASDAQ:PHVS)May 28, 2025 | marketbeat.comNorthern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS)May 28, 2025 | marketbeat.comVR Adviser LLC Has $61.73 Million Stock Holdings in Pharvaris (NASDAQ:PHVS)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Grows Holdings in Pharvaris (NASDAQ:PHVS)May 21, 2025 | marketbeat.comBank of America Securities Keeps Their Sell Rating on Pharvaris (PHVS)May 21, 2025 | theglobeandmail.comPharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming CongressesMay 19, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Shares Sold by Sphera Funds Management LTD.May 18, 2025 | marketbeat.comPatient Square Capital LP Sells 34,738 Shares of Pharvaris (NASDAQ:PHVS)May 16, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Acquired by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comPharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHVS Stock NewsMay 14, 2025 | gurufocus.comPharvaris (PHVS) Target Price Lowered by Cantor Fitzgerald | PHVS Stock NewsMay 14, 2025 | gurufocus.comPharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock NewsMay 14, 2025 | gurufocus.comPharvaris Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comPharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4May 12, 2025 | globenewswire.comPharvaris (PHVS) Projected to Post Earnings on WednesdayMay 9, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Increases Stock Holdings in Pharvaris (NASDAQ:PHVS)May 6, 2025 | marketbeat.comCantor Fitzgerald Forecasts Pharvaris FY2025 EarningsMay 3, 2025 | marketbeat.comPharvaris (PHVS) Shares Cross Above 200 DMAMay 2, 2025 | nasdaq.comPharvaris (NASDAQ:PHVS) Shares Gap Up - Here's WhyMay 1, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Coverage Initiated by Analysts at Cantor FitzgeraldMay 1, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Pharvaris N.V. (PHVS) with Overweight RecommendationApril 30, 2025 | msn.com Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address PHVS Media Mentions By Week PHVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼1.110.58▲Average Medical News Sentiment PHVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼12▲PHVS Articles Average Week Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SpringWorks Therapeutics News Avidity Biosciences News Ultragenyx Pharmaceutical News Protagonist Therapeutics News Ascentage Pharma Group International News Scholar Rock News MoonLake Immunotherapeutics News Metsera News Viking Therapeutics News Kymera Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
